Panacos Pharmaceuticals, Inc.
PANC · OTC
12/31/2007 | 12/31/2006 | 12/31/2005 | 12/31/2004 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -36.6% | -72.9% | -21.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 21,678.9% | 14,681.3% | 5,718.2% | 895.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -20,810.6% | -13,419% | -5,631.8% | -900.4% |
| EPS | -0.7 | -0.75 | -1.72 | -14.51 |
| % Growth | 6.7% | 56.4% | 88.1% | – |
| EPS Diluted | -0.7 | -0.75 | -1.72 | -14.51 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -21,237.8% | -14,416.9% | -3,807.2% | -878.2% |